KX2-391 Dihydrochloride: Dual Src Kinase and Tubulin Inhibitor for Advanced Cancer and Antiviral Research

Executive Summary: KX2-391 dihydrochloride (CAS No. 1038395-65-1) is a small-molecule inhibitor targeting Src kinase and tubulin polymerization with nanomolar potency in cellular assays (APExBIO). It demonstrates effective inhibition of hepatitis B virus (HBV) transcription by disrupting the precore promoter and suppresses botulinum neurotoxin A (BoNT/A) enzymatic activity in vitro. Clinically, KX2-391 is used topically for actinic keratosis and orally for certain cancers, achieving therapeutic plasma levels with good tolerability. Its high solubility in DMSO and ethanol, but not water, enables flexible workflow integration. These properties make KX2-391 a valuable tool in cancer, antiviral, and neurotoxin pathway research (Zhang et al., 2024).

Biological Rationale

Src family kinases are non-receptor tyrosine kinases that regulate cell proliferation, survival, and migration. Aberrant Src activation is implicated in multiple cancers and fibrotic diseases (Zhang et al., 2024). Tubulin polymerization is essential for mitotic spindle assembly, making the cytoskeleton a key target in oncology. Hepatitis B virus (HBV) replication depends on host cell signaling and transcriptional machinery, including Src-mediated pathways. Botulinum neurotoxin A (BoNT/A) cleaves SNAP-25, disrupting neurotransmission and causing flaccid paralysis. Inhibitors like KX2-391 dihydrochloride that block both Src kinase and tubulin polymerization offer a dual mechanism to disrupt tumor cell proliferation, viral replication, and neurotoxin activity.

Mechanism of Action of KX2-391 dihydrochloride

• Src kinase inhibition: KX2-391 binds the substrate-binding site of Src, blocking kinase activity with IC₅₀ values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) (APExBIO).
• Tubulin polymerization inhibition: It interacts with a novel site on the α-β tubulin heterodimer, disrupting cytoskeletal structure at ≥80 nM cellular concentrations.
• HBV transcription suppression: KX2-391 targets the HBV precore promoter, reducing viral RNA with EC₅₀ values of 0.14 μM (PXB cells) and 2.7 μM (HepG2-NTCP) (see extended discussion).
• BoNT/A inhibition: The compound blocks SNAP-25 cleavage by directly inhibiting the BoNT/A light chain at 10–40 μM in vitro.

This dual mechanism disrupts both signal transduction and the cytoskeletal architecture, producing antiproliferative, antiviral, and antitoxin effects.

Evidence & Benchmarks

• KX2-391 inhibits Src kinase activity in NIH3T3/c-Src527F cells with an IC₅₀ of 23 nM and in SYF/c-Src527F cells with an IC₅₀ of 39 nM (APExBIO).
• Disrupts tubulin polymerization in cells at concentrations ≥80 nM, with direct binding to α-β tubulin heterodimer (see mechanistic comparison).
• Suppresses HBV transcription by inhibiting the precore promoter with EC₅₀ values of 0.14 μM (PXB) and 2.7 μM (HepG2-NTCP) (Zhang et al., 2024).
• Blocks BoNT/A SNAP-25 cleavage at 10–40 μM in biochemical assays (APExBIO).
• Oral dosing in mice: 5–15 mg/kg once or twice daily; in chimpanzees: 1 mg/kg twice daily for anti-HBV studies.
• Clinical use: 1% ointment for actinic keratosis; 40–120 mg/day oral dosing in cancer, achieving therapeutic plasma concentrations without significant peripheral neuropathy (see clinical translation).

Applications, Limits & Misconceptions

• Oncology: KX2-391 is utilized as an anticancer agent targeting Src kinase and tubulin polymerization pathways, with proven efficacy in tumor models.
• Virology: Demonstrated to inhibit HBV replication by suppressing the precore promoter.
• Neurotoxin research: Used to block BoNT/A activity in preclinical assays.
• Clinical dermatology: Approved as a topical 1% ointment for actinic keratosis.

For a deeper mechanistic roadmap and translational strategy, see KX2-391 Dihydrochloride: Mechanistic Convergence and Strategy. This article extends the referenced piece by providing atomic-level, updated benchmarks and direct workflow specifications for reproducibility.

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride is not soluble in water; attempts at aqueous dissolution will fail without co-solvents.
• It does not inhibit all tyrosine kinases—selectivity is highest for Src and related family members.
• The compound's efficacy at concentrations below 13 nM is not well-supported in cellular anticancer or antiviral assays.
• Clinical tolerability does not guarantee safety in all preclinical models; off-target effects should be evaluated experimentally.
• KX2-391 does not reverse established fibrosis; its primary action is on signaling and proliferation, not ECM degradation.

Workflow Integration & Parameters

• Solubility: ≥25.2 mg/mL in DMSO, ≥48.8 mg/mL in ethanol (with gentle warming), insoluble in water.
• Storage: Store solid at –20°C, protected from light and moisture.
• In vitro concentrations: 0.013–10 μM for anticancer and anti-HBV studies; 10–40 μM for anti-BoNT/A assays.
• In vivo dosing: Mice: 5–15 mg/kg orally, once or twice daily; Chimpanzees: 1 mg/kg twice daily (anti-HBV studies).
• Clinical dosing: 1% ointment topical (actinic keratosis); 40–120 mg/day oral (tumor therapy).

For practical assay integration and troubleshooting, see scenario-driven solutions for cell-based workflows. This article expands on those scenarios with quantitative protocol guidance and latest evidence.

Conclusion & Outlook

KX2-391 dihydrochloride is a rigorously benchmarked, dual mechanism inhibitor for advanced cancer, HBV, and neurotoxin research. Its atomic-level selectivity for Src kinase and tubulin polymerization, paired with robust clinical and preclinical data, supports its ongoing adoption in translational and mechanistic studies. Sourced from APExBIO, the A3535 kit provides verified quality and stability for reproducible results (APExBIO). Researchers are encouraged to reference the latest mechanistic reviews (see atomic benchmarks) and product documentation for optimal integration into their workflows.